Opko Health, Inc. (OPK)
OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.
Opko Health, Inc. (OPK)‘s Financial Overview
Opko Health, Inc. (OPK) declined -2.51% yesterday to close its trading session at $3.11. The company has 1 year Price Target of $11.9. The stock touched its 52-Week High on Obsolete and 52-Week Low on Obsolete. The stock traded with the volume of 5.53 Million shares yesterday. The firm shows the market capitalization of $1.76 Billion.
Opko Health, Inc. (OPK) reported its last quarterly earnings on 12/30/2017 where the firm reported its Actual EPS of $-0.32/share. The difference between the actual and expected EPS is $-0.24 a share with a surprise factor of -300%.
The firm is trading with SMA20 of -7.85 Percent, SMA50 of SMA50 Percent and SMA200 of -43.58 percent. Opko Health, Inc. has P/S value of 1.65 while its P/B value stands at 0.92. Similarly, the company has Return on Assets of -11.4 percent, Return on Equity of -15.1 percent and Return on Investment of -10.6 Percent. The company shows Gross Margin and Operating Margin of 41.9 percent and -26.2 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 2.2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 6 analysts offering 12-month price forecasts for OPKO Health Inc have a median target of 12.25, with a high estimate of 20.00 and a low estimate of 6.00. The median estimate represents a +293.89% increase from the last price of 3.11.
Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients – it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Bristol-Myers Squibb Company (BMY)‘s Financial Outlook
The 21 analysts offering 12-month price forecasts for Bristol-Myers Squibb Co have a median target of 64.00, with a high estimate of 75.00 and a low estimate of 50.00. The median estimate represents a +2.29% increase from the last price of 62.57.
According to Zacks Investment Research, Bristol-Myers Squibb Company has a Consensus Recommendation of 2.18. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged0.26% and closed its last trading session at $62.57. The company has the market capitalization of $105.26 Billion. The firm touched its 52-Week high on Obsolete and 52-Week low on Obsolete. The company has volume of 5.52 Million shares. The company has a total of 1.68 Billion shares outstanding.
The company has YTD performance of 2.11 percent. Beta for Bristol-Myers Squibb Company stands at 0.93 while its ATR (average true range) is 1.5. The company has Weekly Volatility of 2.80%% and Monthly Volatility of 2.29%.
Bristol-Myers Squibb Company has distance from 20-day Simple Moving Average (SMA20) of -4.85%, Distance from 50-Day Simple Moving Average of SMA50 percent and Distance from 200-Day Simple Moving Average of 2.15%.
The Company currently has ROA (Return on Assets) of 3 percent, Return on Equity (ROE) of 7.2 Percent and Return on Investment (ROI) of 20.2% with Gross margin of 71.5 percent and Operating & Profit margin of 25.2% and 4.8% respectively.